Biomarker-directed, multi-drug, phase 1b trial in bladder cancer

At the European Cancer Congress (ECC) 2015, Hendrik-Tobias Arkenau, MD, PhD, from Sarah Cannon Research Institute UK, London, UK, discusses an open-label, biomarker-directed, multi-drug, multi-center, multi-arm, randomized phase 1b clinical trial in patients with muscle-invasive urothelial carcinoma of the bladder who have progressed on prior treatment.
Share this video  
Similar topics